Risperidone-induced metabolic dysfunction ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Risperidone-induced metabolic dysfunction is attenuated by curcuma longa extract administration in mice
Author(s) :
Auger, Florent [Auteur]
Université de Lille, Droit et Santé
Troubles cognitifs dégénératifs et vasculaires - U1171
Martin, Françoise [Auteur]
Université de Lille, Droit et Santé
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Institut Pasteur de Lille
Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508 [EGID]
Petrault, Olivier [Auteur]
Laboratoire de Physiopathologie de la Barrière Hémato-Encéphalique [LBHE]
Troubles cognitifs dégénératifs et vasculaires - U1171
Samaillie, Jennifer [Auteur]
Université de Lille, Droit et Santé
Groupe de Recherche Interdiscipinaire Innovation et Optimisation Thérapeutique - EA 4481 [GRIIOT]
Hennebelle, Thierry [Auteur]
Université de Lille, Droit et Santé
Groupe de Recherche Interdiscipinaire Innovation et Optimisation Thérapeutique - EA 4481 [GRIIOT]
Trabelsi, Mohamed-Sami [Auteur]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Institut Pasteur de Lille
Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508 [EGID]
Bailleul, François [Auteur]
Université de Lille, Droit et Santé
Groupe de Recherche Interdiscipinaire Innovation et Optimisation Thérapeutique - EA 4481 [GRIIOT]
Staels, Bart [Auteur]
Université de Lille, Droit et Santé
Institut Pasteur de Lille
Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (EGID) - U1011
Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508 [EGID]
Bordet, Regis [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Duriez, Patrick [Auteur]
Université de Lille, Droit et Santé
Troubles cognitifs dégénératifs et vasculaires - U1171
Université de Lille, Droit et Santé
Troubles cognitifs dégénératifs et vasculaires - U1171
Martin, Françoise [Auteur]
Université de Lille, Droit et Santé
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Institut Pasteur de Lille
Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508 [EGID]
Petrault, Olivier [Auteur]
Laboratoire de Physiopathologie de la Barrière Hémato-Encéphalique [LBHE]
Troubles cognitifs dégénératifs et vasculaires - U1171
Samaillie, Jennifer [Auteur]
Université de Lille, Droit et Santé
Groupe de Recherche Interdiscipinaire Innovation et Optimisation Thérapeutique - EA 4481 [GRIIOT]
Hennebelle, Thierry [Auteur]
Université de Lille, Droit et Santé
Groupe de Recherche Interdiscipinaire Innovation et Optimisation Thérapeutique - EA 4481 [GRIIOT]
Trabelsi, Mohamed-Sami [Auteur]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Institut Pasteur de Lille
Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508 [EGID]
Bailleul, François [Auteur]
Université de Lille, Droit et Santé
Groupe de Recherche Interdiscipinaire Innovation et Optimisation Thérapeutique - EA 4481 [GRIIOT]
Staels, Bart [Auteur]
Université de Lille, Droit et Santé
Institut Pasteur de Lille
Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (EGID) - U1011
Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508 [EGID]
Bordet, Regis [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Duriez, Patrick [Auteur]
Université de Lille, Droit et Santé
Troubles cognitifs dégénératifs et vasculaires - U1171
Journal title :
Metabolic Brain Disease
Abbreviated title :
Metab. Brain Dis.
Volume number :
33
Pages :
63-77
Publisher :
Springer Verlag
Publication date :
2018-02-01
ISSN :
0885-7490
English keyword(s) :
Lipids
Atypical antipsychotics
Risperidone
Curcumin
Glucose
Atypical antipsychotics
Risperidone
Curcumin
Glucose
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Antipsychotics, such as risperidone, increase food intake and induce alteration in glucose and lipid metabolism concomitantly with overweight and body fat increase, these biological abnormalities belong to the metabolic ...
Show more >Antipsychotics, such as risperidone, increase food intake and induce alteration in glucose and lipid metabolism concomitantly with overweight and body fat increase, these biological abnormalities belong to the metabolic syndrome definition (high visceral adiposity, hypertriglyceridemia, hyperglycemia, low HDL-cholesterol and high blood pressure). Curcumin is a major component of traditional turmeric (Curcuma longa) which has been reported to improve lipid and glucose metabolism and to decrease weight in obese mice. We questioned the potential capacity of curcumin, contained in Curcuma longa extract (Biocurcuma™), to attenuate the risperidone-induced metabolic dysfunction. Two groups of mice were treated once a week, for 22 weeks, with intraperitoneal injection of risperidone (Risperdal) at a dose 12.5 mpk. Two other groups received intraperitoneal injection of the vehicle of Risperdal following the same schedule. Mice of one risperidone-treated groups and of one of vehicle-treated groups were fed a diet with 0.05% Biocurcuma™ (curcumin), while mice of the two other groups received the standard diet. Curcumin limited the capacity of risperidone to reduce spontaneous motricity, but failed to impede risperidone-induced increase in food intake. Curcumin did not reduce the capacity of risperidone to induce weight gain, but decreased visceral adiposity and decreased the risperidone-induced hepatomegaly, but not steatosis. Furthermore, curcumin repressed the capacity of risperidone to induce the hepatic over expression of enzymes involved in lipid metabolism (LXRα, FAS, ACC1, LPL, PPARγ, ACO, SREBP2) and decreased risperidone-induced glucose intolerance and hypertriglyceridemia. Curcumin decreased risperidone-induced increases in serum markers of hepatotoxicity (ALAT, ASAT), as well as of one major hepatic pro-inflammatory transcription factor (NFκB: p105 mRNA and p65 protein). These findings support that nutritional doses of curcumin contained in Curcuma longa extract are able to partially counteract the risperidone-induced metabolic dysfunction in mice, suggesting that curcumin ought to be tested to reduce the capacity of risperidone to induce the metabolic syndrome in human.Show less >
Show more >Antipsychotics, such as risperidone, increase food intake and induce alteration in glucose and lipid metabolism concomitantly with overweight and body fat increase, these biological abnormalities belong to the metabolic syndrome definition (high visceral adiposity, hypertriglyceridemia, hyperglycemia, low HDL-cholesterol and high blood pressure). Curcumin is a major component of traditional turmeric (Curcuma longa) which has been reported to improve lipid and glucose metabolism and to decrease weight in obese mice. We questioned the potential capacity of curcumin, contained in Curcuma longa extract (Biocurcuma™), to attenuate the risperidone-induced metabolic dysfunction. Two groups of mice were treated once a week, for 22 weeks, with intraperitoneal injection of risperidone (Risperdal) at a dose 12.5 mpk. Two other groups received intraperitoneal injection of the vehicle of Risperdal following the same schedule. Mice of one risperidone-treated groups and of one of vehicle-treated groups were fed a diet with 0.05% Biocurcuma™ (curcumin), while mice of the two other groups received the standard diet. Curcumin limited the capacity of risperidone to reduce spontaneous motricity, but failed to impede risperidone-induced increase in food intake. Curcumin did not reduce the capacity of risperidone to induce weight gain, but decreased visceral adiposity and decreased the risperidone-induced hepatomegaly, but not steatosis. Furthermore, curcumin repressed the capacity of risperidone to induce the hepatic over expression of enzymes involved in lipid metabolism (LXRα, FAS, ACC1, LPL, PPARγ, ACO, SREBP2) and decreased risperidone-induced glucose intolerance and hypertriglyceridemia. Curcumin decreased risperidone-induced increases in serum markers of hepatotoxicity (ALAT, ASAT), as well as of one major hepatic pro-inflammatory transcription factor (NFκB: p105 mRNA and p65 protein). These findings support that nutritional doses of curcumin contained in Curcuma longa extract are able to partially counteract the risperidone-induced metabolic dysfunction in mice, suggesting that curcumin ought to be tested to reduce the capacity of risperidone to induce the metabolic syndrome in human.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
CNRS
INRA
ISA
Inserm
Institut Pasteur de Lille
Univ. Artois
Univ. Littoral Côte d’Opale
Université de Lille
CNRS
INRA
ISA
Inserm
Institut Pasteur de Lille
Univ. Artois
Univ. Littoral Côte d’Opale
Université de Lille
Submission date :
2019-11-27T13:35:57Z
2024-02-19T14:27:09Z
2024-02-19T14:27:09Z
Files
- dy1na
- Open access
- Lien vers l'article fourni par l'éditeur
- Access the document